Stanford Cancer Institute Directory

Translational Oncology Profiles

Showing 21 - 30 of 50
    Harry A. Oberhelman, Jr. and Mark L. Welton Professor

    Bio

    Dr. Kebebew is an internationally recognized expert in Endocrine Oncology and Surgery. He has performed more than three thousand operations on the adrenal, parathyroid and thyroid glands, and for neuroendocrine tumors of the gastrointestinal tract and pancreas. Dr. Kebebew has published over 400 articles, chapters and textbooks, and serves on the editorial board and as a reviewer for 54 biomedical journals. He has received awards from the American Cancer Society, American Association for Cancer Research, American Thyroid Association, American Association of Endocrine Surgeons, and International Association of Endocrine Surgeons.
    Director, ChEM-H, Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and Professor of Chemistry and, by courtesy, of Biochemistry

    Bio

    Research in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health. For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases. For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. Recently, we initiated a collaborative program involving multiple Stanford laboratories (http://med.stanford.edu/virx.html.html) that is aimed at developing a fundamentally new approach to treating viral infections. As part of this initiative, we are developing an antiviral chemotherapy that modulates pyrimidine metabolism in the host, and also a platform to engineer immuno-modulatory glycolipids for the treatment of influenza.
    The George A. and Hilda M. Daubert Professor in Chemistry

    Bio

    Eric Kool received his Ph.D. in Chemistry from Columbia University and did postdoctoral work in nucleic acids chemistry at Caltech. He started his career at the University of Rochester before moving to Stanford in 1999, where he is the George and Hilda Daubert Professor of Chemistry. He teaches Organic Chemistry and Chemical Biology to undergraduate and graduate students. The Kool lab uses the tools of chemistry to study the structures, interactions and biological activities of nucleic acids and the enzymes that process them. Molecular design and synthesis play a major role in this work, followed by analysis of structure and function, both in test tubes and in living systems. These studies are aimed at gaining a better basic understanding of biology, and applying this knowledge to practical applications in biomedicine. As part of this research, members of the group synthesize designer nucleobases and nucleotides, with unusual properties such as fluorescence, enzyme reactivity, or altered shape and H-bonding ability. We use these as tools to study DNA polymerase enzymes, DNA repair pathways, and RNA modifying enzymes. This work is leading to new probes for diagnosis of cancer, useful fluorescent tags for biology, and fluorescent sensors of many species such as cancer metabolites and toxic metals.
    Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
    Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

    Bio

    Dr. Kunz specializes in the treatment of gastrointestinal malignancies with an expertise in the care of patients with neuroendocrine tumors (NETs). She has developed broad investigative programs in the field of neuroendocrine tumors, encompassing clinical trials, population sciences, and translational correlates. She is the Principal Investigator on numerous clinical trials. She is the Director of the Stanford Neuroendocrine Tumor Program. She currently serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel, the Neuroendocrine Tumor Taskforce of the National Cancer institute, the NANETS Guidelines and Executive Committees, and leads the NET Working Group of the Eastern Cooperative Oncology Group (ECOG).
    Professor of Biomedical Data Science, Emeritus
    Professor (Research) of Medicine (Oncology)
    Associate Professor (Research) of Radiation Oncology (Radiation and Cancer Biology) and of Radiology (Molecular Imaging Program at Stanford)
    Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

    Bio

    Dr. Massarweh specializes in breast cancer, with a particular expertise in adjuvant therapy for Hormone-Receptor Positive breast cancer, metastatic breast cancer, and male breast cancer. His research background is in studying endocrine therapy action and resistance mechanisms, as well as targeted therapy to overcome it. His outpatient practice is exclusively dedicated to patients with breast cancer and his philosophy is centered around providing his patients with compassionate expert care. Cancer education and promoting clinical practice innovation is an integral part of his academic and leadership mission. Dr. Massarweh is dedicated to healthcare transformation and using novel approaches to enhance integration of clinical care, research, and education, that is driven by patient centered design. RESEARCH INTERESTS Adjuvant therapy for ER-positive breast cancer Endocrine Resistance Breast Cancer in Men Triple Positive Breast Cancer Clinical Trial Design CLINICAL INTERESTS: Metastatic Breast Cancer Hormone Receptor Positive Breast Cancer Breast Cancer in Men Breast Cancer in Pregnant Women Preoperative Endocrine Therapy
    Professor of Microbiology and Immunology

    Bio

    For complete and up to date information on this and other items, consult my Curriculum vitae (updated, 12/16), and website; URL: http://www.stanford.edu/~amatin/MatinLabHomePage/MatinLabHome-Page.htm

Affiliations

Organizations